These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 18359322)

  • 1. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
    Miller M; Ginsberg HN; Schaefer EJ
    Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol].
    Hayashi T; Hirano T; Shiobara T; Suguro T; Adachi M
    Rinsho Byori; 2006 Jun; 54(6):569-75. PubMed ID: 16872005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lipid and lipoprotein profiles in risk assessment and therapy.
    Ballantyne CM; Hoogeveen RC
    Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High and low density lipoprotein abnormalities in coronary patients with LDL-C at target and uncontrolled HDL-C and triglycerides].
    Posadas-Romero C; Posadas-Sánchez R; Juárez-Rojas JG; Medina-Urrutia A; Jorge-Galarza E; Cardoso-Saldaña G; Caracas-Portilla N; Mendoza-Peŕez E
    Arch Cardiol Mex; 2008; 78(1):30-9. PubMed ID: 18581711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.